 |
|
Clinical and Echocardiographic Follow-up of Patients Previously Treated With Dexfenfluramine or Phentermine/Fenfluramine
Julius M. Gardin, MD;
Neil J. Weissman, MD;
Cyril Leung, MD;
Julio A. Panza, MD;
Daniel Fernicola, MD;
Kelly D. Davis, MD;
Ginger D. Constantine, MD;
Cheryl L. Reid, MD
JAMA. 2001;286:2011-2014.
Context Use of anorexigen therapy is associated with valvular abnormalities, although there is limited information on long-term changes in valvular regurgitation following discontinuation of these agents.
Objective To evaluate changes in valvular regurgitation, valve morphology, and clinical parameters 1 year after an initial echocardiogram in patients previously treated with dexfenfluramine or phentermine/fenfluramine and in untreated controls.
Design and Setting A reader-blinded, multicenter, echocardiographic and clinical 1-year follow-up study at 25 outpatient clinical sites.
Patients A total of 1142 obese patients (1466 participated in the initial study) who had follow-up echocardiogram; all but 4 had a follow-up medical history and physical examination. Follow-up time from discontinuation of drug to follow-up echocardiogram for 371 dexfenfluramine patients was 17.5 months (range, 13-26 months) and for 340 phentermine/fenfluramine patients was 18.7 months (range, 13-26 months) after discontinuation of drug therapy.
Main Outcome Measure Change in grade of valvular regurgitation and valve morphology and mobility.
Results Echocardiographic changes in aortic regurgitation were observed in 8 controls (7 [1.7%] had decreases; 1 [0.2%] had an increase); 29 dexfenfluramine patients (23 [6.4%] had decreases; 6 [1.7%] had increases; P<.001 vs controls); and 15 phentermine/fenfluramine patients (4.5% all decreases; P = .03 vs controls). No statistically significant differences were observed when treated patients were compared with controls for changes in medical history, physical findings, mitral regurgitation, aortic or mitral leaflet mobility or thickness, pulmonary artery systolic pressure, ejection fraction, valve surgery, or cardiovascular events.
Conclusion Progression of valvular abnormalities is unlikely in patients 1 year after an initial echocardiogram and 13 to 26 months after discontinuation of dexfenfluramine and phentermine/fenfluramine.
Author Affiliations: Division of Cardiology, Department of Medicine, University of California, Irvine (Drs Gardin, Leung, and Reid); Cardiovascular Research Institute, Washington Hospital Center, Washington, DC (Drs Weissman and Fernicola); Cardiology Branch, National Heart, Lung, and Blood Institute, Bethesda, Md (Dr Panza); and Wyeth-Ayerst Research, Philadelphia, Pa (Drs Davis and Constantine). Dr Gardin is now with the Division of Cardiology, St John Hospital and Medical Center, Detroit, Mich. Dr Panza is now with the Cardiovascular Research Institute, Washington Hospital Center, Washington, DC.
RELATED ARTICLE
October 24/31, 2001
JAMA. 2001;286(16):2033-2034.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Obesity and Cardiovascular Disease: Pathophysiology, Evaluation, and Effect of Weight Loss: An Update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease From the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism
Poirier et al.
Circulation 2006;113:898-918.
ABSTRACT
| FULL TEXT
Knowledge, Beliefs, and Attitudes of Dental and Dental Hygiene Students Toward Obesity
Magliocca et al.
J Dent Educ 2005;69:1332-1339.
ABSTRACT
| FULL TEXT
Medical Monitoring for Pharmaceutical Injuries: Tort Law for the Public's Health?
Studdert et al.
JAMA 2003;289:889-894.
ABSTRACT
| FULL TEXT
|
